CABA 241220 35.00P (CABA241220P35000) Stock Options, News & Quotes

US OptionsDetailed Quotes

CABA241220P35000

Watchlist

27.10
0.000.00%

15min DelayTrading Jun 20 12:15 ET

0.00High0.00Low

Intraday

5D
Daily

News

Cabaletta Bio Reports Q3 2024 Financial Results
TipRanksNov 18 22:54 ET
Express News | Cabaletta Bio Announces Presentation Of Updated CABA-201 Clinical Data At ACR Convergence 2024l; Says Safety Profile Suggested Favorable Risk-Benefit With No CRS Or ICANS In Majority Of Patients
BenzingaNov 18 07:22 ET
Cabaletta Bio's CABA-201 Shows Results in Autoimmune Disease Trials
BenzingaNov 18 07:11 ET
William Blair Maintains Cabaletta Bio(CABA.US) With Buy Rating
Moomoo NewsNov 18 04:33 ET · Ratings
Cabaletta Bio Is Maintained at Overweight by Wells Fargo
Dow JonesNov 15 14:23 ET · Ratings
H.C. Wainwright Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $25
Moomoo NewsNov 15 11:32 ET · Ratings

Comments

Dps

Oct 10 14:04

$Cabaletta Bio (CABA.US)$ poor stock … not growing at all

Dps

Oct 4 14:30

$Cabaletta Bio (CABA.US)$ what happened to it … no improvement at all

Jaguar8

Sep 25 15:39

NEWS

$Cabaletta Bio (CABA.US)$
Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024
Cabaletta Bio (Nasdaq: CABA) announced two presentations at the upcoming American College of Rheumatology (ACR) Convergence 2024, featuring new and updated clinical data on CABA-201, their 4-1BB-containing fully human CD19-CAR T cell investigational therapy. The presentations will cover:
1. An oral presentation on the safety and efficacy of C...

frogoracletrading

Aug 19 09:00

$CABA Support / Resistance Levels

Testing the bottom of the GAP at 4.82. Here are the levels to keep on watch.
Larger Image: tradingview.com...
$Cabaletta Bio (CABA.US)$

Meltyy

Mar 20 10:18

Biotech Stock News 3/20

$Annovis Bio (ANVS.US)$ 22% Ph2/3 data reporting update
$Taysha Gene Therapies (TSHA.US)$ 21% FY 2023 results
$TFF Pharmaceuticals (TFFP.US)$ 14% Clinical programs update
$Jaguar Health (JAGX.US)$ 14% Crofelemer commercialization
$Acelyrin (SLRN.US)$ 4% Ph1/2 positive data
$Delcath Systems (DCTH.US)$ 3% Closes $7M private placement
$Sellas Life Sciences (SLS.US)$ 0% Closes $20M offering & private placement
$Immunic (IMUX.US)$ 1% Patent notice of allowance
$Nurix Therapeutics (NRIX.US)$ 0...